---
schema_version: "secwatch.filing_event.v1"
accession: "0001826667-25-000049"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:33:34.774019+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q1 rev $9.2M (+42% YoY); revises 2025 guidance: 50% growth, no adj. EBITDA positive

## Summary
- Net sales $9.2M, up 42% YoY and 11% sequential; gross margin 84% vs 85%.
- Net loss available to common $10.4M ($0.39 diluted loss per share) vs $13.2M ($0.60) prior year.
- Adjusted EBITDA loss narrowed to $5.5M from $10.4M; cash $13.0M at Mar 31, then raised $22M via private placement.
- 2025 guidance: confirms 50% rev growth; no longer expects adj. EBITDA or cash flow positive in 2025.
- Agreement with 55% of preferred shareholders to simplify capital structure; preferred conversion by mid-July 2025.

## SEC filing metadata
- accession: 0001826667-25-000049
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000049/0001826667-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000049/tlsi-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826667-25-000049
- JSON: https://secwatch.observer/filing/0001826667-25-000049.json
- Plain text: https://secwatch.observer/filing/0001826667-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.